Fig 2: Increased YBX1 in the nucleus contributes to VEGFB expression. a Representative image labeled for YBX1, VEGFB, and DAPI. Scale bar, 50 µm (n = 3). b Continuous intrathecal administration of YBX1 siRNA prevented the upregulation of VEGFB mRNA induced by SNL (*P < 0.05, **P < 0.01 vs. sham group, ##P < 0.01 vs. corresponding scramble group, two-tailed one-way ANOVA, n = 5). c YBX1 siRNA (i.t.) attenuated the VEGFB protein upregulation on day 14 after SNL (*P < 0.05, **P < 0.01 vs. sham group, #P < 0.05 vs. corresponding scramble group, two-tailed one-way ANOVA, n = 4). d Suppression of transportin-1 by transportin-1 siRNA (i.t.) decreased YBX1 accumulation in the nucleus (**P < 0.01 vs. sham group, ##P < 0.01 vs. corresponding scramble group, two-tailed one-way ANOVA, n = 4). e, f Intrathecal injection of transportin-1 attenuated VEGFB upregulation on day 14 after SNL (*P < 0.05, **P < 0.01 vs. sham group, #P < 0.05 vs. corresponding scramble group, two-tailed one-way ANOVA, n = 5 for (e) and n = 4 for (f)). The data are presented as the mean ± s.e.m. Source data are available as a Source Data file

Fig 3: CircAnks1a promoted the nuclear translocation of YBX1 following SNL. a Exogenous linearized circAnks1a bound to YBX1 on day 14 following SNL (n = 3). b RNA pulldown assay showed that SNL significantly increased the interaction of endogenous circAnks1a and YBX1 in the dorsal horn (n = 3). c The amount of circAnks1a precipitated by YBX1 was obviously increased on day 14 following SNL (*P < 0.05 vs. the sham group, two-tailed two-sample t tests, n = 4). d Two potential YBX1 motifs were observed in circAnks1a. e High-resolution image showing that binding of circAnks1a to YBX1 occurred in both the nucleus (arrow) and the cytoplasm (arrowhead). Scale bar, 1 µm (n = 3). f The level of nuclear YBX1 was significantly increased on days 7 and 14 after SNL (**P < 0.01 vs. the sham group, two-tailed one-way ANOVA, n = 4). g Suppression of circAnks1a by intrathecal injection of circAnks1a siRNA inhibited the increase in nuclear YBX1 on day 14 after SNL (**P < 0.01 vs. sham group, ##P < 0.01 vs. corresponding scramble group, two-tailed one-way ANOVA, n = 4). h Overexpression of circAnks1a by intraspinal injection of AAV-circAnks1a-EGFP increased the level of YBX1 in the nucleus (*P < 0.05 vs. AAV-EGFP group, two-tailed one-way ANOVA, n = 4). i CircAnks1a siRNA significantly attenuated the increase in YBX1 immunoprecipitation by transportin-1 antibody on day 14 after SNL (**P < 0.01 vs. sham group, ##P < 0.01 vs. corresponding scramble group, two-tailed one-way ANOVA, n = 4). j Intraspinal injection of AAV-circAnks1a-EGFP increased the amount of YBX1 in the immunocomplex precipitated by transportin-1 (**P < 0.01 vs. the AAV-EGFP group, two-tailed one-way ANOVA, n = 4). The data are presented as the mean ± s.e.m. Source data are available as a Source Data file